We addressed tumor specificity in CD8+ T cells and the ability of these T cells to recognize dominant and subdominant tumor antigens by looking at real-time T cell lytic function in tumors and lymphoid tissue using an in vivo CTL assay. The gene discussed is CD8A; the disease is neoplasm.